Key facts
At a glance
The numbers you need before deciding.
Weight loss
20.9%
Monthly cost
$299–$449/mo
How you take it
Weekly injection
Main side effect
Nausea
Fat vs lean
75% fat
If you stop
~11% regain
Before you start
Learn about this treatment
Everything you'd want to know before deciding.
On treatment
Already taking this?
Practical guides for people currently on this medication.
Compare
Side-by-side comparisons
See how this drug compares with another, side by side.
Clinical evidence
How it compares in trials
Average weight loss % — from individual phase 3 trials
Body composition and what happens after stopping
What does the lost weight consist of?
Resistance training (weight lifting, bodyweight exercises) can significantly reduce the muscle loss. Aim for 2–3 sessions per week during weight loss.
Source: SURMOUNT-1 body scan sub-study
What happens when you stop
Source: SURMOUNT-4 (2024)
medication
after stopping
after 1 year
In studies, people regained about 53% of the weight they lost within a year of stopping — ending about 9.9% below their starting weight. This is the body returning to its defended weight — not a personal failure. Current evidence supports long-term use for people who respond well.
Is this right for you?
Who this tends to fit
Relevant if you
- Open to a weekly injection
- Want a weekly injection with large trial data (SURMOUNT-1: up to 20.9%)
- Comfortable with a higher monthly cost ($299–$449/month)
- BMI 30+ or 27+ with health conditions
Not right if you
- You have a personal or family history of medullary thyroid cancer
- You have a history of pancreatitis
- You are pregnant or planning to become pregnant
- Your BMI is below 27 without qualifying health conditions
Prefer a pill? Wegovy (semaglutide) is available as a daily pill for $149–$299/month and shows similar weight loss in trials.
Safety
Important cautions
- In animal studies, tirzepatide caused thyroid tumours. It is unknown whether this applies to humans, but it is not prescribed to people with a personal or family history of medullary thyroid cancer.
- Stop taking and contact your doctor immediately if you have persistent severe abdominal pain — this may be a sign of pancreatitis.
- This drug may increase the risk of gallbladder problems. Tell your doctor if you develop sudden upper abdominal pain.
Read the boxed warning explained in full. See what the label says about pregnancy and breastfeeding. Availability varies by pharmacy — check current shortage status.
Practical guide
How to take Zepbound & Mounjaro
Inject under the skin of your thigh, abdomen, or upper arm — once per week, on the same day each week
Starting dose is 2.5mg. Your doctor will increase it every 4 weeks — up to a maximum of 15mg
Store in the refrigerator (36–46°F). Can be kept at room temperature for up to 21 days if needed
Each pen is pre-filled and single-use — no dose preparation needed
Common questions
FAQ
For the full regain timeline, week by week, see what the trials found after stopping.
Questions to ask your doctor
- →Am I a good candidate given my health history and any other conditions I have?
- →Do I have any contraindications I should know about?
- →What results should I realistically expect, and over what timeframe?
- →Which side effects should make me contact you?
- →How long should I try this before we decide if it's working?
- →What happens if I need to stop — how do I come off it safely?
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Sources & references
- [1]SURMOUNT-12,539 adults with obesity or overweight with comorbidities, no type 2 diabetes · 72 weeksUp to 20.9% average weight loss at the highest dose (15 mg). About 9 in 10 people lost ≥5% of body weight; more than half lost ≥20%. Discontinuation due to side effects: 4.3–7.1% vs. 2.6% placebo.New England Journal of Medicine (2022) ↗
- [2]SURMOUNT-3Adults with obesity after an intensive lifestyle intervention achieving ≥5% weight loss · 72 weeksAdditional 18.4% mean weight loss after the initial lifestyle-induced loss — total mean loss of ~26% from original baseline.Nature Medicine (2024) ↗
- [3]SURMOUNT-4Adults with obesity who had completed a 36-week tirzepatide lead-in phase · 88 weeks total (36-week lead-in + 52-week randomised phase)25.3% total weight loss over the full 88-week period. Stopping drug led to 14.0% weight regain vs. 5.5% additional loss in those who continued.JAMA (2024) ↗
- [4]SURMOUNT-5 (head-to-head vs. semaglutide)Adults with obesity or overweight, no type 2 diabetes · 72 weeksTirzepatide was superior to semaglutide 2.4 mg on body weight reduction and waist circumference — the first direct head-to-head superiority trial between these two drugs.New England Journal of Medicine (2025) ↗
- [5]SURMOUNT-1 Body Composition Substudy160 participants from SURMOUNT-1 with DXA scans · 72 weeks~75% of weight lost was fat mass, ~25% lean mass. Total lean mass change: –10.9% tirzepatide vs. –2.6% placebo.Obesity (2024) ↗